Minreksav (Cytisinicline)

Cytisinicline acts as a partial agonist at the α4β2 subtype of neuronal nicotinic acetylcholine receptors. It delivers a modest stimulatory signal that mimics nicotine, lowering cravings, while simultaneously blocking nicotine from fully activating the receptors, which diminishes the rewarding effect of smoking.

The specific dose of Minreksav is determined by the prescribing healthcare professional based on the individual’s medical condition, smoking history, and response to therapy. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety data for Cytisinicline in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Minreksav, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Minreksav’s active ingredient, Cytisinicline, is a partial agonist of nicotinic receptors, similar to varenicline but with a distinct binding profile that may result in different tolerability. Both aim to reduce cravings, yet individual response and side‑effect patterns can vary, making physician assessment essential for choosing the most suitable option.

Minreksav should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity to maintain its stability and efficacy.

Minreksav is taken orally, typically as a tablet swallowed whole with water. It is usually taken at the same time each day, and patients should follow the dosing schedule prescribed by their healthcare professional to achieve optimal results.

Serious risks include mood alterations such as worsening depression or anxiety, cardiovascular events like chest pain or irregular heartbeat, and severe allergic reactions that may present as rash, swelling or anaphylaxis. Patients should seek immediate medical attention if any of these symptoms occur.

Minreksav is contraindicated in individuals with known hypersensitivity to Cytisinicline or any tablet excipients, in patients under 18 years of age, and in those with uncontrolled severe cardiovascular disease. Anyone with a history of serious psychiatric disorders should discuss suitability with a healthcare provider.